Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Debra Ainge

- PMLiVE

Wilmington Healthcare has relaunched as HSJ Information

The new company covers HSJ, HSJ Advisory, HSJ Marketing Solutions and HSJ Market Intelligence

Bridging Gaps with Virtual Meetings – Perks of Virtual Medical Education

Learn how virtual meetings can be used to review new data and minimize lengthy presentations, making every in-person interaction more productive and focused. Dive into the synergistic benefits of combining...

Impetus Digital

Bayer symbol

Bayer and NextRNA Therapeutics enter oncology partnership worth $547m

The companies will advance small molecule therapeutics against a new class of targets for cancer

- PMLiVE

Roche’s monoclonal antibody PiaSky approved by EC to treat rare blood disorder PNH

The drug is now the first monthly subcutaneous treatment authorised for use in this patient population

EU flag

EC approves Celltrion’s Stelara biosimilar SteQeyma for inflammatory diseases

The drug has been authorised for use in gastroenterology, dermatology and rheumatology indications

- PMLiVE

Artificial intelligence versus real insight – does pharmaceutical industry consulting face a dilemma or a progression?

By Frank Fisher and Zoë van Helmond

Amiculum

- PMLiVE

Origins Shares The 3 Must-Have Metrics to Showcase the True Value of Patient Engagement

Demonstrating the value of patient focus is key to securing future investment. At Origins, we advocate for having three key metrics for each patient focused activity we conduct: activity, outcome...

Origins – The Patient Focused Specialists

- PMLiVE

Johnson & Johnson’s Rybrevant combination approved by EC for expanded lung cancer use

Approximately 484,306 cases of lung cancer were diagnosed in Europe in 2022

- PMLiVE

Merck’s Winrevair receives EC approval to treat pulmonary arterial hypertension in adults

About 30,000 people in the EU are living with the progressive blood vessel disorder

- PMLiVE

Novartis announces positive late-stage results for Leqvio monotherapy in atherosclerotic CVD

Cardiovascular disease, including heart disease and stroke, is the leading cause of death globally

- PMLiVE

Empowering NHS engagement through tailored real-world data dashboards

In today’s complex healthcare environment, engaging effectively with NHS decision-makers is more crucial than ever. Earlier this summer, Iain Shield (Associate Director – Market Access, Mtech Access) and Ben Spurr...

Petauri Evidence

regeneron headquarters

Regeneron’s Ordspono granted EC approval to treat non-Hodgkin lymphomas

The decision marks the first regulatory approval of the drug globally for these patients

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links